Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005866 · ClinicalTrials.gov registry record · Phase 3
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT00005866 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 240 participants.
The verdict
NCT00005866, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. It is not yet known if total-body irradiation plus peripheral stem cell transplantation is more effective with busulfan or with cyclophosphamide for myelodysplastic syndrome or acute myeloid leukemia. PURPOSE: Randomized phase III trial to compare the effectiveness of busulfan with that of cyclophosphamide in patients undergoing total-body irradiation plus peripheral stem cell transplantation for advanced myelodysplastic syndrome or related acute myeloid leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG methotrexate
- DRUG busulfan
- PROCEDURE allogeneic bone marrow transplantation
- DRUG cyclosporine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2000-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005866
The ClinicalTrials.gov registry entry for NCT00005866 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00005866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005866 about?
NCT00005866 is a clinical study titled "S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia". RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. It is not yet known if total-body irradiation plus peripheral stem cell transplantation is more effective with busulfan or with cyclo...
What is the current status of trial NCT00005866?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2000-02. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00005866?
The interventions under investigation include: cyclophosphamide (DRUG), methotrexate (DRUG), busulfan (DRUG), allogeneic bone marrow transplantation (PROCEDURE), cyclosporine (DRUG).
Who is sponsoring clinical trial NCT00005866?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.